Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Enhanced Anti-Cancer Potential: Investigating the Combined Effects with Coriolus versicolor Extract and Phosphatidylinositol 3-Kinase Inhibitor (LY294002) In Vitro

T. Jędrzejewski, J. Sobocińska, B. Maciejewski, M. Slovakova, S. Wrotek

. 2025 ; 26 (4) : . [pub] 20250212

Language English Country Switzerland

Document type Journal Article

Grant support
"Excellence Initiative - Research University" program (Mobility for employees, 9th edition) Nicolaus Copernicus University

Coriolus versicolor (CV), known in traditional Chinese medicine for over 2000 years, is currently used in China and Japan to reduce chemotherapy or radiotherapy side effects in cancer patients. Despite extensive research, its effects still need improvement. This study aimed to determine if combining CV extract with LY294002, an inhibitor of the phosphatidylinositol-3-kinase (PI3K) signalling pathway, enhances cancer cell treatment, potentially leading to a novel therapeutic approach. Three human cancer cell lines (MCF-7, HeLa, and A549) were treated with CV extract alone or combined with LY294002. Cell viability was assessed using MTT assays. Then, HeLa and MCF-7 cells most sensitive to the co-treatment were used to evaluate colony formation, apoptosis, cell cycle, cell migration and invasion, and phospho-PI3K expression. The results demonstrated that LY294002 enhanced the CV extract's anti-tumour effects by reducing cell viability and colony formation. The combined treatment with CV extract and LY294002 more effectively induced G0/G1 cell cycle arrest, promoted apoptosis, reduced cell invasion and migration, and inhibited phospho-PI3K expression compared to each agent alone. This study highlights the potent cytotoxic enhancement between CV extract and LY294002 on cancer cells, primarily by inhibiting phospho-PI3K expression. These findings suggest promising avenues for developing novel combination therapies targeting cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009890
003      
CZ-PrNML
005      
20250429135217.0
007      
ta
008      
250415s2025 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms26041556 $2 doi
035    __
$a (PubMed)40004020
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Jędrzejewski, Tomasz $u Department of Immunology, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, Lwowska 1 Str., 87-100 Toruń, Poland $1 https://orcid.org/0000000189505643
245    10
$a Enhanced Anti-Cancer Potential: Investigating the Combined Effects with Coriolus versicolor Extract and Phosphatidylinositol 3-Kinase Inhibitor (LY294002) In Vitro / $c T. Jędrzejewski, J. Sobocińska, B. Maciejewski, M. Slovakova, S. Wrotek
520    9_
$a Coriolus versicolor (CV), known in traditional Chinese medicine for over 2000 years, is currently used in China and Japan to reduce chemotherapy or radiotherapy side effects in cancer patients. Despite extensive research, its effects still need improvement. This study aimed to determine if combining CV extract with LY294002, an inhibitor of the phosphatidylinositol-3-kinase (PI3K) signalling pathway, enhances cancer cell treatment, potentially leading to a novel therapeutic approach. Three human cancer cell lines (MCF-7, HeLa, and A549) were treated with CV extract alone or combined with LY294002. Cell viability was assessed using MTT assays. Then, HeLa and MCF-7 cells most sensitive to the co-treatment were used to evaluate colony formation, apoptosis, cell cycle, cell migration and invasion, and phospho-PI3K expression. The results demonstrated that LY294002 enhanced the CV extract's anti-tumour effects by reducing cell viability and colony formation. The combined treatment with CV extract and LY294002 more effectively induced G0/G1 cell cycle arrest, promoted apoptosis, reduced cell invasion and migration, and inhibited phospho-PI3K expression compared to each agent alone. This study highlights the potent cytotoxic enhancement between CV extract and LY294002 on cancer cells, primarily by inhibiting phospho-PI3K expression. These findings suggest promising avenues for developing novel combination therapies targeting cancer.
650    _2
$a lidé $7 D006801
650    12
$a chromony $x farmakologie $7 D002867
650    12
$a morfoliny $x farmakologie $7 D009025
650    12
$a pohyb buněk $x účinky léků $7 D002465
650    12
$a inhibitory fosfoinositid-3-kinasy $x farmakologie $7 D000081082
650    12
$a apoptóza $x účinky léků $7 D017209
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a MFC-7 buňky $7 D061986
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a HeLa buňky $7 D006367
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a rostlinné extrakty $x farmakologie $x chemie $7 D010936
650    _2
$a signální transdukce $x účinky léků $7 D015398
650    _2
$a buněčný cyklus $x účinky léků $7 D002453
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a synergismus léků $7 D004357
650    _2
$a buňky A549 $7 D000072283
650    _2
$a fosfatidylinositol-3-kinasy $x metabolismus $7 D019869
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sobocińska, Justyna $u Department of Immunology, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, Lwowska 1 Str., 87-100 Toruń, Poland $1 https://orcid.org/0000000346409533
700    1_
$a Maciejewski, Bartosz $u Department of Immunology, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, Lwowska 1 Str., 87-100 Toruń, Poland $1 https://orcid.org/0000000334968805
700    1_
$a Slovakova, Marcela $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573 Str., 532 10 Pardubice, Czech Republic $1 https://orcid.org/0000000249750983 $7 xx0105097
700    1_
$a Wrotek, Sylwia $u Department of Immunology, Faculty of Biological and Veterinary Sciences, Nicolaus Copernicus University, Lwowska 1 Str., 87-100 Toruń, Poland $1 https://orcid.org/0000000187447822
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 26, č. 4 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40004020 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135213 $b ABA008
999    __
$a ok $b bmc $g 2311338 $s 1246971
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 26 $c 4 $e 20250212 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a "Excellence Initiative - Research University" program (Mobility for employees, 9th edition) $p Nicolaus Copernicus University
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...